This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
3op0
From Proteopedia
(Difference between revisions)
m (Protected "3op0" [edit=sysop:move=sysop]) |
|||
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{STRUCTURE_3op0| PDB=3op0 | SCENE= }} | ||
| - | ===Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR pY1069 peptide=== | ||
| - | == | + | ==Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR pY1069 peptide== |
| - | [[http://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN | + | <StructureSection load='3op0' size='340' side='right'caption='[[3op0]], [[Resolution|resolution]] 2.52Å' scene=''> |
| - | + | == Structural highlights == | |
| - | ==Function== | + | <table><tr><td colspan='2'>[[3op0]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OP0 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3OP0 FirstGlance]. <br> |
| - | [ | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.52Å</td></tr> |
| - | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CSD:3-SULFINOALANINE'>CSD</scene>, <scene name='pdbligand=CSO:S-HYDROXYCYSTEINE'>CSO</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NI:NICKEL+(II)+ION'>NI</scene>, <scene name='pdbligand=PTR:O-PHOSPHOTYROSINE'>PTR</scene></td></tr> | |
| - | == | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3op0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3op0 OCA], [https://pdbe.org/3op0 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3op0 RCSB], [https://www.ebi.ac.uk/pdbsum/3op0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3op0 ProSAT]</span></td></tr> |
| - | + | </table> | |
| - | + | == Disease == | |
| - | + | [https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. | |
| - | <references | + | == Function == |
| + | [https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> Isoform 2 may act as an antagonist of EGF action.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| - | [[Category: Arrowsmith | + | [[Category: Large Structures]] |
| - | [[Category: Ayinampudi | + | [[Category: Arrowsmith CH]] |
| - | [[Category: Bountra | + | [[Category: Ayinampudi V]] |
| - | [[Category: Bullock | + | [[Category: Bountra C]] |
| - | [[Category: Canning | + | [[Category: Bullock A]] |
| - | [[Category: Chaikuad | + | [[Category: Canning P]] |
| - | [[Category: Cooper | + | [[Category: Chaikuad A]] |
| - | + | [[Category: Cooper CDO]] | |
| - | [[Category: Edwards | + | [[Category: Edwards AM]] |
| - | [[Category: Guo | + | [[Category: Guo K]] |
| - | [[Category: Krojer | + | [[Category: Krojer T]] |
| - | [[Category: Muniz | + | [[Category: Muniz JRC]] |
| - | + | [[Category: Ugochukwu E]] | |
| - | [[Category: Ugochukwu | + | [[Category: Vollmar M]] |
| - | [[Category: Vollmar | + | [[Category: Weigelt J]] |
| - | [[Category: Weigelt | + | [[Category: Von Delft F]] |
| - | [[Category: | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Crystal structure of Cbl-c (Cbl-3) TKB domain in complex with EGFR pY1069 peptide
| |||||||||||
Categories: Homo sapiens | Large Structures | Arrowsmith CH | Ayinampudi V | Bountra C | Bullock A | Canning P | Chaikuad A | Cooper CDO | Edwards AM | Guo K | Krojer T | Muniz JRC | Ugochukwu E | Vollmar M | Weigelt J | Von Delft F
